1356055-09-8

Basic information

• Product Name: 4-(5-iodopyrimidin-4-yl)morpholine
• Synonyms: 4-(5-iodopyrimidin-4-yl)morpholine;4-(5-iodo-4-pyrimidinyl)morpholine
• CAS NO: 1356055-09-8
• Molecular Formula: C₈H₁₀IN₃O
• Molecular Weight: 291.08897
• Mol File: 1356055-09-8.mol

Chemical Properties

• Boiling Point: 379.9±42.0 °C(Predicted)
• Appearance: /
• Density: 1.805±0.06 g/cm3(Predicted)
• PKA: 5.83±0.27(Predicted)
• CAS DataBase Reference: 4-(5-iodopyrimidin-4-yl)morpholine(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(5-iodopyrimidin-4-yl)morpholine(1356055-09-8)
• EPA Substance Registry System: 4-(5-iodopyrimidin-4-yl)morpholine(1356055-09-8)

Safety Data

• Hazardous Substances Data: 1356055-09-8(Hazardous Substances Data)

Upstream product

• 110-91-8 morpholine 
• 63558-65-6 4-chloro-5-iodopyrimidine 

Downstream Products

• 1356054-60-8 4-(5-(1-(4-fluorophenyl)-1H-pyrazolo[3,4-b]pyridin-4-yl)pyrimidin-4-yl)morpholine 
• 1357094-16-6 N-(3-methoxy-4-(4-morpholinopyrimidin-5-yl)phenyl)methanesulfonamide 
• 1428880-33-4 3-(4-fluoro-2-methoxyphenyl)-7-(4-morpholinopyrimidin-5-yl)benzo[d]isoxazole 
• 1428880-04-9 3-(4-fluorophenyl)-7-(4-morpholinopyrimidin-5-yl)benzo[d]isoxazole 
• 1428880-71-0 3-(2-methoxyphenyl)-7-(4-morpholinopyrimidin-5-yl)benzo[d]isoxazole 
• 1428880-24-3 3-(5-fluoro-2-methoxyphenyl)-7-(4-morpholinopyrimidin-5-yl)benzo[d]isoxazole 

Relevant articles and documents

SUBSTITUTED BICYCLIC HETEROARYL COMPOUNDS

Disclosed are azaindazole compounds of Formula (I): or a pharmaceutically acceptable salt thereof, wherein: X is O and Y is N; or X is S and Y is CH; Z is CR2 or N; Q is a heteroaryl; and R1 is defined herein. Also disclosed are methods of using such compounds in the treatment of at least one CYP17 associated condition, such as, for example, cancer, and pharmaceutical compositions comprising such compounds.

AZAINDAZOLE COMPOUNDS

Disclosed are azaindazole compounds of Formula (I), or pharmaceutically acceptable salts thereof, wherein W is CR4 or N; and R1, R2, R3, and R4 are defined herein. Also disclosed are methods of using such compounds in the treatment of at least one CYP17 associated condition, such as, for example, cancer, and pharmaceutical compositions comprising such compounds.

SULFONAMIDE COMPOUNDS USEFUL AS CYP17 INHIBITORS

Disclosed are sulfonamide compounds of Formula (I): or stereoisomers, N-oxides, prodrugs, or pharmaceutically acceptable salts thereof, wherein ring A, R1, R2, R3, R4 and R5 are defined herein. Also disclosed are methods of using such compounds in the treatment of conditions related to CYP17 enzyme, such as cancer, and pharmaceutical compositions comprising such compounds.